An investigation has been announced for long-term investors in shares of DexCom, Inc. The company has recently made several announcements, including the upcoming release of its Q2 2026 earnings and the launch of new products such as the Dexcom Flex CGM System and the reimagined Stelo App. The impact of these developments on DexCom's investment narrative and its position in the market is unclear, with some outlets suggesting the company is poised for growth and others indicating it may face competition from rivals such as Abbott.